What amount sold does Chanticleer Holdings, Inc. report in Form D filings?

The latest linked filings report $25.4M sold across 12 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Chanticleer Holdings, Inc.'s most recent SEC filing?

Chanticleer Holdings, Inc.'s most recent Form D filing was on 2024-12-23.

How many investors does Chanticleer Holdings, Inc. have?

The most recent Form D filing lists 4 investor(s).

What type of securities does Chanticleer Holdings, Inc. offer?

Chanticleer Holdings, Inc.'s SEC Form D filings indicate equity offerings.

Chanticleer Holdings, Inc.

CIK: 0001106838·Biotechnology·PRINCETON, NJ·Corporation

Reported Sold

$25,404,249

Total Filings

Identified Offerings

Last Filed

Dec 23, 2024

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Dec 23, 2024Form D — New notice

Reported sold: $3,918,000 · Target: $3,918,000

Rule 506(b)·4 investors

Jul 17, 2023Form D — New notice

Reported sold: $2,250,000 · Target: $2,250,000

Rule 506(b)·1 investor

Aug 19, 2022Form D — New notice

Reported sold: $2,250,000 · Target: $2,250,000

Rule 506(b)·5 investors

May 16, 2018Form D — New notice

Reported sold: $1,411,249 · Target: $1,411,249

Rule 506(b)·13 investors

May 11, 2017Form D — New notice

Reported sold: $6,000,000 · Target: $6,000,000

Rule 506(b)·14 investors

Mar 18, 2015Form D — New notice

Reported sold: $1,000,000 · Target: $1,000,000

Rule 506(b)·1 investor

Jan 16, 2015Form D — New notice

Reported sold: $1,150,000 · Target: $1,150,000

Rule 506(b)·12 investors

Nov 20, 2013Form D — New notice

Reported sold: $800,000 · Target: $800,000

Rule 506(b)·3 investors·Section 4(a)(5)

Oct 22, 2013Form D — New notice

Reported sold: $2,500,000 · Target: $2,500,000

Rule 506(c)·23 investors·Section 4(a)(5)

Oct 15, 2013Form D — New notice

Reported sold: $0 · Target: Indefinite

Rule 506(c)·193 investors·Section 4(a)(5)

Aug 13, 2013Form D — New notice

Reported sold: $3,000,000 · Target: $3,000,000

Rule 506·7 investors·Section 4(6)

Nov 30, 2011Form D — New notice

Reported sold: $1,125,000 · Target: $1,125,000

Rule 506·7 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$1,092,856

Amendment Rate

Latest reported sold across 12 identified offerings

$25,404,249

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Eric Lederer

Related Person

Appears on 7 filings

Paul Moskowitz

Related Person

Appears on 6 filings

Keith Johnson

Related Person

Appears on 6 filings

Michael Carroll

Related Person

Appears on 6 filings

Michael D Pruitt

Related Person

Appears on 6 filings

Russell J. Page

Related Person

Appears on 5 filings

Michael Pruitt

Related Person

Appears on 3 filings

Raghu Rao

Related Person

Appears on 3 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Dec 23, 2024	New	$3,918,000	$3,918,000	4
Jul 17, 2023	New	$2,250,000	$2,250,000	1
Aug 19, 2022	New	$2,250,000	$2,250,000	5
May 16, 2018	New	$1,411,249	$1,411,249	13
May 11, 2017	New	$6,000,000	$6,000,000	14
Mar 18, 2015	New	$1,000,000	$1,000,000	1
Jan 16, 2015	New	$1,150,000	$1,150,000	12
Nov 20, 2013	New	$800,000	$800,000	3
Oct 22, 2013	New	$2,500,000	$2,500,000	23
Oct 15, 2013	New	Indefinite	$0	193
Aug 13, 2013	New	$3,000,000	$3,000,000	7
Nov 30, 2011	New	$1,125,000	$1,125,000	7

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Hepion Pharmaceuticals, Inc.

Biotechnology

Offering target: $3,055,000

Filed Aug 5, 2026